Skip to content

Blood Pressure Variability in Non-hypertensive Patients With Ischemic Cerebrovascular Disease

Blood Pressure Variability in Non-hypertensive Patients With Ischemic Cerebrovascular Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05232240
Acronym
BPV-NhICVD
Enrollment
300
Registered
2022-02-09
Start date
2022-02-14
Completion date
2028-02-29
Last updated
2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure Variability, Ischemic Cerebrovascular Disease

Keywords

ischemic stroke, transient ischemic attack, non-hypertensive, blood pressure variability, vascular risk

Brief summary

This study is a single-center prospective cohort of patients with ischemic cerebrovascular disease (ICVD) who have not met the diagnostic criteria for hypertension. Ambulatory 24-hour blood pressure monitoring (ABPM) will be performed at baseline and one year after the enrollment. The primary purpose of the study is to delineate the relationship of blood pressure variability (BPV) with the risk of composite vascular events in non-hypertensive patients with ICVD. The factors related to BPV, as well as the potential modulators of the associations between BPV and vascular risk, will be further explored among these patients.

Detailed description

Hypertension is one of the most important risk factors of ischemic cerebrovascular disease (ICVD), while various blood pressure variability (BPV) indices are immerging as novel prognostic indicators independent of the blood pressure level. However, the BPV profiles without hypertension have not been specifically observed. Considering the great importance of blood pressure management in ICVD, more research is needed to clarify whether and how BPV will increase the vascular risk in non-hypertensive patients with ICVD. This prospective cohort study will be helpful to invoke an early management of blood pressure in patients with ICVD before the clinical establishment of hypertension. All eligible non-hypertensive patients hospitalized for ICVD will be consecutively enrolled in this cohort. Blood pressure measurements are obtained with ambulatory 24-hour blood pressure monitoring (ABPM) every 20 minutes during day-time (6:00-22:00) and every 30 minutes during night-time (22:00-6:00) at baseline and one year after the enrollment. The clinical, imaging and laboratory information will be collected at baseline. During an estimated 3-year follow-up, the vessel-related diagnostic or monitoring procedures, treatment, functional status and new vascular events will be recorded by web-based patients' self-reports and investigators' regular telephone visits.

Interventions

DIAGNOSTIC_TESTblood pressure variability measured by ambulatory 24-hour blood pressure monitoring

The ambulatory 24-hour blood pressure monitoring will be performed at baseline and one year after the enrollment. Various blood pressure variability characteristics will be obtained from these examinations.

Sponsors

Xuanwu Hospital, Beijing
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Diagnosed as ischemic stroke or transient ischemic attack (TIA), with confirmation of computed tomography or magnetic resonance imaging. 2. Less than 90 days after onset of ischemic stroke or TIA symptoms. 3. The blood pressure measured 5\ 90 days after the ICVD onset without any anti-hypertension treatment is less than 140/90 mmHg (an average of ≥2 readings obtained on ≥ 2 occasions after emptying bladder, relaxing for more than 5 min, and avoiding caffeine, exercise, or smoking for at least 30 min before measurement). 4. Consent to participate in the study.

Exclusion criteria

1. A definite diagnosis of hypertension. 2. Under anti-hypertension treatment. 3. Worsening neurological conditions. 4. With a National Institute of Health Stroke Scale score more than 5 points. 5. Intracranial hemorrhage. 6. Autonomic failure. 7. With malignant tumors or poor organ functions or hematologic diseases, whose estimated life expectancy is less than 3 years. 8. With contraindications to ambulatory 24-hour blood pressure monitoring or fail to finish the examination at baseline. 9. Mental disease. 10. Pregnant.

Design outcomes

Primary

MeasureTime frameDescription
3-year risk of Major Adverse Cardiovascular Event3 yearsthe time of first documented cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction or unstable angina

Secondary

MeasureTime frameDescription
1-year rate of Major Adverse Cardiovascular Event1 yearthe rate of cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, and unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina
1-year rate of Ischemic Stroke1 yearthe rate of fatal and nonfatal ischemic stroke
1-year rate of Acute Coronary Syndrome1 yearthe rate of first documented fatal and nonfatal myocardial infarction and unstable angina
90-day Functional Outcome90 dayspercentage of patients with modified Rankin Scale (mRS) scores (minimum 0 and maximum 5) 3 to 5, who are considered to be disabled
3-year risk of Ischemic Stroke3 yearsthe time of first documented fatal or nonfatal ischemic stroke
3-year risk of Acute Coronary Syndrome3 yearsthe time of first documented fatal or nonfatal myocardial infarction or unstable angina
3-year risk of Cardiovascular Mortality3 yearsthe time of mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death
1-year rate of Cardiovascular Mortality1 yearthe rate of mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, and unobserved sudden death

Countries

China

Contacts

Primary ContactXin Ma, MD, PhD
maxin118@hotmail.com13501390691

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026